Aaron Lisberg, MD, on TROPION-Lung01 Trial and Antibody-Drug Conjugates

Posted: Thursday, February 1, 2024

Aaron Lisberg, MD, of the University of California, Los Angeles, discusses the findings of the TROPION-Lung01 trial and comparing the antibody-drug conjugate datopotamab deruxtecan with standard therapies for advanced or metastatic NSCLC.

---